Navigation Links
Endoscopic Carpal Tunnel Release System

ProductsEndoscopic Carpal Tunnel Release System
Company Arthrex
Item Endoscopic Carpal Tunnel Release System
Features 
  • One-incision technique
  • Reusable instrumentation
  • Cost-effective
  • Single use blade
  • Proven
    • Description The Endoscopic Carpal Tunnel Release System is a single-portal system consisting of a set of precision stainless steel instruments used in conjunction with a sharp single use blade. The slotted instrument sheath incorporates a wide longitudinal slot to provide unsurpassed visual control with a 4 mm scope while following the blade. The system includes a set of dilators and an adjustable handle on the Slotted Instrument Sheath for ease of use. The published clinical success rate for the single-portal approach to carpal tunnel syndrome (CTS) surgery varies between 94 and 100%.
    Info Arthrex
    Customer Service: (800) 933-7001
    Web site: http://www.arthrex.com

    Related medicine products :

    1. OME-7000 Endoscopic and Navigation Assisted Surgical Microscope
    2. EU-M60 Endoscopic Ultrasound Center
    3. VASOVIEW 5 Endoscopic Vessel Harvesting System
    4. The Endotrac™ System For Endoscopic Carpal Tunnel Releases (ECTR)
    5. VASOVIEW 6 Endoscopic Vessel Harvesting System
    6. Strange Endoscopic Cholangiography Catheter
    7. Suture Assistant - Endoscopic Suturing Device
    8. LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier
    9. Reflex ELC® Endoscopic Clip Applier
    10. ENDOPATH ETS45 Endoscopic Linear Cutters
    11. ENDOPATH ETS-Flex45 Endoscopic Articulating Linear Cutters
    Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Fitness Might Limit Strokes Impact 51687 1Fitness Might Limit Strokes Impact 51687 2